153 related articles for article (PubMed ID: 33381908)
1. The Best Pharmaceuticals for Children Act and Pediatric Research Equity Act reach the age of majority-An oncology perspective.
Bernhardt MB; Lindsay H; Allen-Rhoades W; Foster JH
Pediatr Blood Cancer; 2021 Mar; 68(3):e28871. PubMed ID: 33381908
[TBL] [Abstract][Full Text] [Related]
2. Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: What can the obstetric community learn from the pediatric experience?
Ren Z; Zajicek A
Semin Perinatol; 2015 Nov; 39(7):530-1. PubMed ID: 26455383
[TBL] [Abstract][Full Text] [Related]
3. Safety monitoring of drugs granted exclusivity under the Best Pharmaceuticals for Children Act: what the FDA has learned.
Mathis LL; Iyasu S
Clin Pharmacol Ther; 2007 Aug; 82(2):133-4. PubMed ID: 17632537
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the Impact of Mandated Postmarketing Pediatric-Focused Safety Reviews on Safety-Related Regulatory Actions 2013-2019.
Mohamoud M; Cheng C; Ryan D; Kim I; Wu E; Muñoz M; Kortepeter C; Pinnow E; Dal Pan G
Clin Pharmacol Ther; 2023 Jun; 113(6):1368-1377. PubMed ID: 37021630
[TBL] [Abstract][Full Text] [Related]
5. Dermatology Drugs for Children-U.S. Food and Drug Administration Perspective.
Epps RE
Dermatol Clin; 2022 Jul; 40(3):289-296. PubMed ID: 35750412
[TBL] [Abstract][Full Text] [Related]
6. Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children.
Vinks AA; Emoto C; Fukuda T
Clin Pharmacol Ther; 2015 Sep; 98(3):298-308. PubMed ID: 26073179
[TBL] [Abstract][Full Text] [Related]
7. Measuring the patient health, societal and economic benefits of US pediatric therapeutics legislation.
Vernon JA; Shortenhaus SH; Mayer MH; Allen AJ; Golec JH
Paediatr Drugs; 2012 Oct; 14(5):283-94. PubMed ID: 22775493
[TBL] [Abstract][Full Text] [Related]
8. The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing.
Breslow LH
Harvard J Legis; 2003; 40(1):133-93. PubMed ID: 16594116
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
Berry MD
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
[No Abstract] [Full Text] [Related]
10. FDA Safety Reviews on Drugs, Biologics, and Vaccines: 2007-2013.
Cope JU; Rosenthal GL; Weinel P; Odegaard A; Murphy DM
Pediatrics; 2015 Dec; 136(6):1125-31. PubMed ID: 26598453
[TBL] [Abstract][Full Text] [Related]
11. The National Institutes of Health and the Best Pharmaceuticals for Children Act.
Zajicek A
Paediatr Drugs; 2009; 11(1):45-7. PubMed ID: 19127953
[TBL] [Abstract][Full Text] [Related]
12. Microdosing Studies in Children: A US Regulatory Perspective.
Roth-Cline M; Nelson RM
Clin Pharmacol Ther; 2015 Sep; 98(3):232-3. PubMed ID: 26095312
[TBL] [Abstract][Full Text] [Related]
13. A review of the experience with pediatric written requests issued for oncology drug products.
Akalu AY; Meng X; Reaman GH; Ma L; Yuan W; Ye J
Pediatr Blood Cancer; 2021 Feb; 68(2):e28828. PubMed ID: 33245181
[TBL] [Abstract][Full Text] [Related]
14. Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislation.
Benning TJ; Shah ND; Inselman JW; Van Houten HK; Ross JS; Wyatt KD
Clin Trials; 2021 Dec; 18(6):732-740. PubMed ID: 34269090
[TBL] [Abstract][Full Text] [Related]
15. Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act.
Hwang TJ; Orenstein L; Kesselheim AS; Bourgeois FT
JAMA Pediatr; 2019 Jan; 173(1):68-74. PubMed ID: 30452498
[TBL] [Abstract][Full Text] [Related]
16. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
Beninger P; Murray M
Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
[TBL] [Abstract][Full Text] [Related]
17. Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development.
Rivera DR; Hartzema AG
Ann Pharmacother; 2014 Mar; 48(3):369-79. PubMed ID: 24311725
[TBL] [Abstract][Full Text] [Related]
18. The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications: introduction.
Shane R
Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S2-3. PubMed ID: 19966076
[No Abstract] [Full Text] [Related]
19. Regulatory Factors Influencing Usage of Retinal Pharmaceuticals: A Look Both Home and Abroad.
Croft DE; Wykoff CC; Michels S; Chakravarthy U; Cruess AF
Am J Ophthalmol; 2016 Sep; 169():xiv-xvi. PubMed ID: 27485923
[No Abstract] [Full Text] [Related]
20. Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012-2018.
Tanaudommongkon I; John Miyagi S; Green DJ; Burnham JM; van den Anker JN; Park K; Wu J; McCune SK; Yao L; Burckart GJ
Clin Pharmacol Ther; 2020 Nov; 108(5):1018-1025. PubMed ID: 32394430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
